Showing 1 - 12 results of 12 for search '"Antibodies/immunoconjugates"', query time: 0.02s Refine Results
  1. 1
    Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2
    Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

    Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors by Kristoffer Staal Rohrberg (15009138)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Table S3 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases

    Table S3 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary... by Noor Jailkhani (16015810)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Table S2 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases

    Table S2 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary... by Noor Jailkhani (16015810)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases

    Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary... by Noor Jailkhani (16015810)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: